Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1994 1
1996 1
2005 3
2007 1
2008 1
2010 1
2011 1
2012 3
2013 1
2014 1
2015 5
2016 3
2017 3
2019 4
2020 6
2022 1
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Bakris GL, et al. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Free article. Clinical Trial.
BACKGROUND: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. ...Eligible patients had a urinary albumin-to-creatinine ratio (with …
BACKGROUND: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials inv …
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Free article. Clinical Trial.
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary …
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with t …
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators. Ruilope LM, et al. Am J Nephrol. 2019;50(5):345-356. doi: 10.1159/000503712. Epub 2019 Oct 30. Am J Nephrol. 2019. PMID: 31665733 Free PMC article. Clinical Trial.
However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. PATIENTS AND METHODS: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of …
However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. PATIENTS AND METHODS: T …
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial.
However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. METHODS: The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease -(FIDELIO-DKD) trial aims to assess the efficacy and safety o …
However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. METHODS: The Finerenone …
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
Réa D, Boquimpani C, Mauro MJ, Minami Y, Allepuz A, Maheshwari VK, D'Alessio D, Wu Y, Lawrance R, Narbutas S, Sharf G, Hochhaus A. Réa D, et al. Leukemia. 2023 May;37(5):1060-1067. doi: 10.1038/s41375-023-01888-y. Epub 2023 Apr 14. Leukemia. 2023. PMID: 37069326 Free PMC article. Clinical Trial.
Health-related quality of life (HRQOL) reported by patients is key to understanding the benefit and impact of treatment on patients' lives, and is becoming increasingly important as the life expectancy of CML-CP patients increases and patients require long-term treatment. …
Health-related quality of life (HRQOL) reported by patients is key to understanding the benefit and impact of treatment on patients' lives, …
Late-Onset Anti-GABAB Receptor Encephalitis: Clinical Characteristics and Outcomes Differing From Early-Onset Patients.
Sun T, Zhao D, Zhang G, Huang Y, Guo J, Jiang W, Jia R, Maimaiti M, Liu J, Bu N, Li Z, Yan Y, Zhang X, Sun C, Zhao C, Jia X, Mao B, Tian H, Liu Y, Chen Z, Fan Z, Guo X, Lu J, Ren K, Li H, Guo J. Sun T, et al. Neurol Neuroimmunol Neuroinflamm. 2023 May 25;10(4):e200131. doi: 10.1212/NXI.0000000000200131. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37230544 Free PMC article.
This study aims to explore the demographic, clinical characteristics, and prognostic differences between late-onset and early-onset GABA(B)R-E and identify predictors of favorable long-term outcomes. METHODS: This is an observational retrospective study conducted in 19 cen …
This study aims to explore the demographic, clinical characteristics, and prognostic differences between late-onset and early-onset GABA(B)R …
Cognitive impairment and stroke in elderly patients.
Lo Coco D, Lopez G, Corrao S. Lo Coco D, et al. Vasc Health Risk Manag. 2016 Mar 24;12:105-16. doi: 10.2147/VHRM.S75306. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27069366 Free PMC article. Review.
Meanwhile, according to the most recent knowledge, optimal stroke care should also include cognitive assessment in the short and long term, and great efforts should be oriented toward a multidisciplinary approach, including quality-of-life assessment and support of caregiv …
Meanwhile, according to the most recent knowledge, optimal stroke care should also include cognitive assessment in the short and long ter …
Endometrial ablation for heavy menstrual bleeding.
Munro MG. Munro MG. Curr Opin Obstet Gynecol. 2005 Aug;17(4):381-94. doi: 10.1097/01.gco.0000175356.25932.c0. Curr Opin Obstet Gynecol. 2005. PMID: 15976544 Review.
PURPOSE OF REVIEW: This review evaluates the currently available evidence regarding resectoscopic endometrial ablation (REA) and the various nonresectoscopic endometrial ablation (NREA) techniques used for heavy menstrual bleeding. ...Levonorgestrel-releasing intrauterine …
PURPOSE OF REVIEW: This review evaluates the currently available evidence regarding resectoscopic endometrial ablation (REA) and the …
Lipohypertrophy and Insulin: An Update From the Diabetes Technology Society.
Tian T, Aaron RE, Huang J, Yeung AM, Svensson J, Gentile S, Forbes A, Heinemann L, Seley JJ, Kerr D, Klonoff DC. Tian T, et al. J Diabetes Sci Technol. 2023 Nov;17(6):1711-1721. doi: 10.1177/19322968231187661. Epub 2023 Aug 9. J Diabetes Sci Technol. 2023. PMID: 37555266
Chest CT-based Assessment of 1-year Outcomes after Moderate COVID-19 Pneumonia.
Bocchino M, Lieto R, Romano F, Sica G, Bocchini G, Muto E, Capitelli L, Sequino D, Valente T, Fiorentino G, Rea G. Bocchino M, et al. Radiology. 2022 Nov;305(2):479-485. doi: 10.1148/radiol.220019. Epub 2022 May 10. Radiology. 2022. PMID: 35536134 Free PMC article.
BACKGROUND: COVID-19 pneumonia may lead to pulmonary fibrosis in the long term. Chest CT is useful to evaluate changes in the lung parenchyma over time. ...
BACKGROUND: COVID-19 pneumonia may lead to pulmonary fibrosis in the long term. Chest CT is useful to evaluate changes in the lung pa …
40 results